Dr. Reddy’s Laboratories has announced its consolidated financial results for the quarter and year ended March 31, 2026. For the full fiscal year, the company reported revenues of ₹335.9 billion, reflecting a 3.2% annual growth. Despite strong underlying business performance, results were impacted by lower lenalidomide sales and one-time expenses related to restructuring, provisions, and new regulatory labour codes.
Annual and Quarterly Performance
For the fiscal year 2025-26, Dr. Reddy’s achieved a consolidated revenue of ₹335.9 billion. The Q4FY26 (January-March 2026) period reported revenues of ₹75.2 billion, representing an 11.6% decline compared to the same period last year. The profit after tax attributable to equity holders for the full year stood at ₹42.9 billion, while the fourth quarter profit was ₹2.2 billion.
Segment Analysis
The Global Generics segment remained the primary revenue driver, contributing ₹299.0 billion for the full year, a 3% growth year-on-year. The Pharmaceutical Services and Active Ingredients (PSAI) segment recorded annual revenues of ₹34.8 billion, a 3% increase. Performance was bolstered by expansion in the India market and robust demand in Europe, where revenue grew by 55% for the year.
Strategic Highlights
During Q4FY26, the company reached several key milestones, including the launch of generic Semaglutide in Canada and India, and the acquisition of Progynova® to foray into Hormone Replacement Therapy in India. The company also completed the integration of 95% of its acquired Consumer Healthcare business in the Nicotine Replacement Therapy (NRT) sector.
Dividend and Governance
The Board has recommended a final dividend of ₹8/- per equity share of face value ₹1/- for the financial year 2025-26, subject to shareholder approval. The record date for the dividend is set for July 10, 2026. Additionally, the company announced the re-appointment of Dr. K P Krishnan as an Independent Director and the appointment of Mr. Srikanth Velamakanni as an Independent Director, both for five-year terms.
Source: BSE
